Doctors are not safe with some patients.

Published Date: 16 Feb 2023

Many physicians have encountered one or more serious or potentially dangerous patients over the years, and according to Medscape research, patient trust has declined.

Read Full News

Latest News

Biomarker to Bedside: Practical Approaches to HER2 Testing and Targeted Treatment in Gynecologic Cancers

Biomarker to Bedside: Practical Approaches to HER2 Testing and Targeted Treatment in Gynecologic Cancers

From Pathways to Practice: Improving Outcomes for Veterans With Metastatic Hormone-Sensitive Prostate Cancer

From Pathways to Practice: Improving Outcomes for Veterans With Metastatic Hormone-Sensitive Prostate Cancer

Bladder Issues Linger in Kids Treated for Ureter Swelling

Many children surgically treated for a swelling at the end of the ureter have lasting bladder symptoms, such as holding urine or trouble passing stools.

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Practical Implications of Targeted Therapies in mHSPC Care

Practical Implications of Targeted Therapies in mHSPC Care

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Latest News

Biomarker to Bedside: Practical Approaches to HER2 Testing and Targeted Treatment in Gynecologic Cancers

From Pathways to Practice: Improving Outcomes for Veterans With Metastatic Hormone-Sensitive Prostate Cancer

Many children surgically treated for a swelling at the end of the ureter have lasting bladder symptoms, such as holding urine or trouble passing stools.

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Practical Implications of Targeted Therapies in mHSPC Care

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

News All Time

Latest Clinical Data for Emerging Combination Strategies in mHSPC

Latest Clinical Data for Emerging Combination Strategies in mHSPC

Redefining MIBC Standards: Multidisciplinary Insights on Optimizing Immunotherapy-Based Combinations

Redefining MIBC Standards: Multidisciplinary Insights on Optimizing Immunotherapy-Based Combinations

Shaping the Future of Muscle-Invasive Bladder Cancer Treatment With the Integration of Immunotherapy and Multidisciplinary Care

Shaping the Future of Muscle-Invasive Bladder Cancer Treatment With the Integration of Immunotherapy and Multidisciplinary Care

Towards Personalized Treatment in mHSPC: Latest Evidence for Biomarker-Targeted Therapies and Multidisciplinary Toxicity Management

Towards Personalized Treatment in mHSPC: Latest Evidence for Biomarker-Targeted Therapies and Multidisciplinary Toxicity Management

Advancing mHSPC Management: From Clinical Guidelines to Emerging Biomarker-Directed Therapies

Advancing mHSPC Management: From Clinical Guidelines to Emerging Biomarker-Directed Therapies

Optimizing mHSPC Care: Integrating Novel Combination Therapies and the Strategies for Multidisciplinary Management

Optimizing mHSPC Care: Integrating Novel Combination Therapies and the Strategies for Multidisciplinary Management

Personalized Decision-Making for Patients With Advanced HSPC

Personalized Decision-Making for Patients With Advanced HSPC

Too Much or Too Little Opioid Pain Relief May Drive Refills After Urologic Surgery

Discharge prescription mismatch versus inpatient dose significantly increased refill rate

Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer

POTOMAC data support a year's worth of immuontherapy paired with BCG induction and maintenance

Half of Patients With Post-BCG Bladder Cancer Achieve CR With Nonviral Gene Therapy

Detalimogene voraplasmid lead to numerous durable complete responses with favorable safety

Low-Intensity Ultrasound Shatters Kidney Stones in 70% of SOUND Trial Patients

Non-invasive, no-anesthesia lithotripsy recently gained FDA approval

Major Complete Response Rate in Very High-Risk Bladder Cancer With Combo Treatment

Only three of 37 patients did not achieve CR at 6 months with pembrolizumab and BCG

Temporary Prostatic Urethra Expander for BPH/LUTS Shows Durable Results

Study showed immediate improvement in symptoms after intentional retrieval of device at 6 months

Evidence Mounts for Darolutamide Plus ADT in Hormone-Sensitive Prostate Cancer

U.S. study supports findings from a global trial using an external control arm

He Inserted a Cable in His Penis. 10 Years Later, He Needed Surgery.

Patient in his 60s eventually developed sepsis

Erectile Dysfunction May Predispose Older Men to Multiple Types of Substance Abuse

Significantly higher risk of sedative, opioid, cocaine abuse compared with no ED diagnosis

Recommended News For You

Stem Cell Transplant Linked to Longer Survival in CMML

Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.

PSA Screening May Modestly Curb Prostate Cancer Deaths

Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects

FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug

Mutation Clearance After Transplant Linked to Better Outcomes in Myelofibrosis

High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer

Recommended Articles For You

Neonatal Hematopoietic Transition and Blood Cell Maturation 

Hematology Laboratory Simulation: Advancing Clinical Competence through Technology-Driven Training 

RIBOTAC Therapy for Oncogenic RNA: A Paradigm Shift in Targeted Cancer Treatment 

Quality of Life Through Personalized Survivorship Navigation After Multimodal Cancer Therapy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC

2.

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

3.

Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.

4.

Tennessee Pharmacies Sell Potent Ivermectin Pushed by Anti-Vaccine Doctor

5.

Exercise can counter detrimental effects of cancer treatment, review suggests

1.

Toxicity Monitoring of Tumor-Targeted Degraders: Clinical Strategies and Emerging Evidence

2.

Tumor Ecosystem Profiles for Therapy Matching

3.

Early Detection of Breast Cancer: Signs, Symptoms, and Screening Methods

4.

The Power of Romiplostim in Treating Low Platelet Counts 

5.

Cancer Survivorship Services in Communities: Clinical Advances, Challenges, and the Path Forward

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V

2.

Navigating the Complexities of Ph Negative ALL - Part XV

3.

Expert Perspectives on Hematology

4.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

5.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot